What happens when you take cbd with sertraline?
Sertraline is a selective serotonin reuptake inhibitor (SSRI) used widely for depression, anxiety, PTSD, OCD, and panic disorder. Its metabolism is multi-pathway, involving CYP2B6, CYP2C19, CYP2C9, CYP3A4, and CYP2D6, with CYP2C19 playing a meaningful role in N-demethylation. Cannabidiol (CBD) is a potent inhibitor of CYP2C19 (and also CYP3A4 and CYP2C9). When CBD is added to a stable sertraline regimen, the slowed clearance can raise sertraline exposure.
A 2022 case report in Innovations in Pharmacy described a 78-year-old man with a CYP2C19 intermediate-metabolizer genotype who had been stable on sertraline 100 mg/day for two decades. After starting an over-the-counter CBD oil, he developed progressive cognitive dysfunction and severe hyponatremia (low sodium), a known but uncommon SSRI adverse effect. The clinicians attributed the deterioration to CBD-induced phenoconversion - effectively converting an intermediate metabolizer into a poor metabolizer through CYP2C19 inhibition, pushing sertraline exposure into a range that triggered SIADH-like hyponatremia.
Why is this important?
SSRIs are some of the most commonly prescribed medications in the United States, and CBD is one of the fastest-growing categories of self-purchased wellness products. Many patients take SSRIs for years and add CBD for sleep or anxiety without realizing the same therapeutic target is involved. The interaction with sertraline is rarely catastrophic, but it can produce a meaningful tilt toward dose-dependent side effects: nausea, GI upset, headache, tremor, sweating, agitation, sexual dysfunction, and - as the case report illustrates - hyponatremia in older adults.
The risk is not uniform across patients. People who are CYP2C19 poor or intermediate metabolizers by genotype already start with higher sertraline exposure, and CBD inhibition pushes them further. Older adults are more vulnerable to SSRI-induced hyponatremia because of comorbid diuretic use, lower lean body mass, and age-related ADH dysregulation. Patients on other serotonergic drugs (tramadol, triptans, linezolid, MAOIs, St. John's wort, other SSRIs/SNRIs) carry a small but real serotonin syndrome risk that any pharmacokinetic boost to sertraline could amplify.
What should you do?
For most patients on stable, low-to-moderate-dose sertraline, adding CBD is not contraindicated, but it should be a discussed decision rather than a silent addition.
- Tell the prescriber before starting, stopping, or escalating CBD on top of sertraline.
- Start CBD low and go slow. Typical consumer CBD doses of 10-25 mg/day produce smaller CYP2C19 inhibition than the high anti-seizure doses used in Epidiolex trials.
- Watch for sertraline side effects: nausea, diarrhea, headache, tremor, jitteriness, sweating, sexual dysfunction, vivid dreams, agitation, or insomnia worsening after CBD starts.
- Watch for hyponatremia signs, particularly in older adults: confusion, headache, nausea, weakness, fatigue, gait unsteadiness, muscle cramps. A basic metabolic panel checking serum sodium is reasonable if symptoms develop.
- Be cautious with other serotonergic agents: tramadol, triptans (sumatriptan, rizatriptan), MAOIs, linezolid, methylene blue, St. John's wort, 5-HTP, and other SSRIs/SNRIs.
- Do not stop sertraline abruptly; SSRIs require gradual taper to avoid discontinuation symptoms.
Which specific products are affected?
Sertraline is sold as Zoloft and many generics; the oral concentrate and tablet forms are equally affected because the interaction is at the metabolism level. The CBD interaction is a class effect across pharmaceutical Epidiolex and consumer CBD products including oils, tinctures, gummies, capsules, vapes, beverages, and topicals applied over large areas. Full-spectrum and broad-spectrum hemp products that contain CBD plus minor cannabinoids and trace THC behave similarly. Other SSRIs metabolized via CYP2C19 - citalopram (Celexa) and escitalopram (Lexapro) - have similar interaction profiles with CBD and warrant the same caution. Fluoxetine and paroxetine are less CYP2C19-dependent but have their own CBD interactions through CYP2D6 inhibition (with paroxetine acting as the inhibitor).
The bottom line
CBD inhibits CYP2C19 and can raise sertraline exposure, with a published case report linking the combination to hyponatremia and cognitive dysfunction in a vulnerable older adult. Most patients can use both with prescriber input and careful symptom monitoring, but the addition of CBD to stable sertraline should be treated as a medication change rather than a harmless wellness add-on - particularly in older adults, CYP2C19 intermediate/poor metabolizers, and patients on other serotonergic drugs.